Bio-Path Holdings, Inc. is a development-stage company. The Company, through its wholly owned subsidiary, Bio-Path, Inc., is engaged in the business of financing and facilitating the development of cancer therapeutics. It has two exclusive licenses from The University of Texas M. D. Anderson Cancer Center for three lead products and nucleic acid delivery technology. These licenses specifically provide drug delivery platform technology with composition of matter intellectual property that enables systemic delivery of antisense, small interfering ribonucleic acid (RNA) (siRNA) and small molecules for treatment of cancer. BP-100-1.01 is the Company’s lead lipid delivery ribonucleic acid interference (RNAi) drug, which will be clinically tested for validation in acute myeloid leukemia, myelodysplastic syndrome and chronic myelogenous leukemia. BP-100-2.01 is the Company’s lead siRNA drug, which will be clinically tested for validation as a targeted ovarian cancer therapeutic agent.